Literature DB >> 2642530

Selective loss of beta 2-microglobulin mRNA in human colon carcinoma.

F Momburg1, S Koch.   

Abstract

Expression of MHC class I antigens requires the intracellular assembly of HLA-A,B,C H chains and beta 2-microglobulin (beta 2m). We have investigated the expression of free H chain, beta 2m, and their mRNAs in tissue sections of colon carcinomas that were defective for the native two-chain molecule. In all of these tumors, beta 2m protein and mRNA were found to be completely absent from the neoplastic cells, whereas free H chains and their respective mRNAs were present in abundance in the tumor cell cytoplasm. The selective abrogation of beta 2m expression represents a unique mechanism leading to a complete loss of class I antigen surface expression in vivo.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2642530      PMCID： PMC2189171          DOI： 10.1084/jem.169.1.309

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  21 in total

Review 1.  MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

2.  Epitopic analysis of detergent-solubilized HLA molecules by solid-phase radioimmunoassay.

Authors:  F A Lemonnier; N Rebai; P P Le Bouteiller; B Malissen; D H Caillol; F M Kourilsky
Journal:  J Immunol Methods       Date:  1982-10-15       Impact factor: 2.303

3.  Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules.

Authors:  H L Ploegh; H T Orr; J L Strominger
Journal:  Cell       Date:  1981-05       Impact factor: 41.582

4.  Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens.

Authors:  F M Brodsky; W F Bodmer; P Parham
Journal:  Eur J Immunol       Date:  1979-07       Impact factor: 5.532

5.  Cell-free translation of the mRNAs for the heavy and light chains of HLA-A and HLA-B antigens.

Authors:  H L Ploegh; L E Cannon; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

6.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

7.  Control of expression of histocompatibility antigens (H-2) and beta 2-microglobulin in F9 teratocarcinoma stem cells.

Authors:  C M Croce; A Linnenbach; K Huebner; J R Parnes; D H Margulies; E Appella; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

8.  Expression of HLA-A, -B, and -C and beta 2-microglobulin antigens in human choriocarcinoma cell lines.

Authors:  J Trowsdale; P Travers; W F Bodmer; R A Patillo
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

9.  Structure of wild-type and mutant mouse beta 2-microglobulin genes.

Authors:  J R Parnes; J G Seidman
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

10.  The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon.

Authors:  F Rosa; H Berissi; J Weissenbach; L Maroteaux; M Fellous; M Revel
Journal:  EMBO J       Date:  1983       Impact factor: 11.598
View more
  11 in total

Review 1.  Biological treatment for liver tumor and new potential biomarkers.

Authors:  Maurizio Chiriva-Internati; Fabio Grizzi; Mitchell S Wachtel; Marjorie Jenkins; Raffaele Ferrari; Everardo Cobos; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

2.  The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer.

Authors:  Craig Blum; Amanda Graham; Matt Yousefzadeh; Jessica Shrout; Katie Benjamin; Murli Krishna; Raza Hoda; Rana Hoda; David J Cole; Elizabeth Garrett-Mayer; Carolyn Reed; Michael Wallace; Michael Mitas
Journal:  Int J Oncol       Date:  2008-09       Impact factor: 5.650

3.  Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area.

Authors:  B Ostenstad; T Lea; E Schlichting; M Harboe
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

Review 4.  Prospects for immunotherapy of malignant disease.

Authors:  E C Morris; G M Bendle; H J Stauss
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

5.  Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.

Authors:  Barbara Seliger; Robert Stoehr; Diana Handke; Anja Mueller; Soldano Ferrone; Bernd Wullich; Andrea Tannapfel; Ferdinand Hofstaedter; Arndt Hartmann
Journal:  Cancer Immunol Immunother       Date:  2009-10-07       Impact factor: 6.968

6.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Authors:  N P Restifo; F M Marincola; Y Kawakami; J Taubenberger; J R Yannelli; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

7.  Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma.

Authors:  J R Goepel; R C Rees; K Rogers; C J Stoddard; W E Thomas; L Shepherd
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

8.  Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses.

Authors:  R Glas; L Franksson; C Une; M L Eloranta; C Ohlén; A Orn; K Kärre
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

9.  Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells.

Authors:  R Glas; K Sturmhöfel; G J Hämmerling; K Kärre; H G Ljunggren
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

Review 10.  Is mucinous carcinoma of the colorectum a distinct genetic entity?

Authors:  C Hanski
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.